We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Study Identifies Optimal Blood Tests for Detection and Treatment of Early Stage Alzheimer’s

By LabMedica International staff writers
Posted on 02 Dec 2022

A new study has identified which blood tests are best at detecting Alzheimer’s disease during the earliest stages, and also another blood test that is optimal for detecting relevant treatment effects. More...

These findings will speed up the development of new therapies that can slow down the disease progression.

The study led by researchers at Lund University (Lund, Sweden) and University of Gothenburg (Gothenburg, Sweden) looked at several newly development blood tests for Alzheimer’s disease pathology and neurodegeneration in 575 individuals from the BioFINDER cohort. In 242 participants, the plasma tests were repeated for up to six years, along with cognitive testing and magnetic resonance imaging. The study revealed that multiple blood biomarkers, namely phospho-tau231 and Aβ42/40, were sufficient in identifying Alzheimer’s disease pathology, even in participants with no symptoms and thus, could be used as strategy to select the correct individuals for novel disease modifying trials – a task which currently requires expensive molecular imaging technique or lumbar punctures.

Yet, over the six years tested, it was shown that only phospho-tau217 was related to Alzheimer’s disease pathology, a decline in cognitive performance and increased brain atrophy typical of incipient Alzheimer’s. Therefore, phospho-tau217 will be an ideal marker for detection of relevant disease-modifying effects of novel interventions. An important aspect of this study was that p-tau217 was able to monitor such changes in pathology and cognition at very early stages of the disease process. The study has large implications on the use of blood test in the recently reported anti-Aβ trials.

“Distinctive blood tests may be optimal for the identification of Alzheimer’s pathology or for monitoring of disease progression and therefore have different roles in clinical trials,” explained Dr. Nicholas Ashton from the University of Gothenburg, first author of the research study. “This study has shown that phospho-tau217 is uniquely placed to be an optimal test for monitoring patients in both a clinical setting and a trial setting because of its longitudinal association with Alzheimer’s development.”

“Besides improving the design of clinical trials, the novel blood tests will revolutionize the diagnoses of early stages of Alzheimer’s disease,” added Oskar Hansson. “Further, phospoho-tau217 might be used in the future to monitor the response in individual patients to disease-modifying therapies in clinical practice.”

Related Links:
Lund University
University of Gothenburg


Gold Member
Serological Pipets
INTEGRA Serological Pipets
Collection and Transport System
PurSafe Plus®
New
HBV DNA Test
GENERIC HBV VIRAL LOAD VER 2.0
New
Gold Member
Automatic Hematology Analyzer
DH-800 Series
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: New research points to protecting blood during radiation therapy (Photo courtesy of 123RF)

Pioneering Model Measures Radiation Exposure in Blood for Precise Cancer Treatments

Scientists have long focused on protecting organs near tumors during radiotherapy, but blood — a vital, circulating tissue — has largely been excluded from dose calculations. Each blood cell passing through... Read more

Immunology

view channel
Image: The VENTANA HER2 (4B5) test is now CE-IVDR approved (Photo courtesy of Roche)

Companion Diagnostic Test Identifies HER2-Ultralow Breast Cancer and Biliary Tract Cancer Patients

Breast cancer is the most common cancer in Europe, with more than 564,000 new cases and 145,000 deaths annually. Metastatic breast cancer is rising in younger populations and remains the leading cause... Read more

Pathology

view channel
Image: An adult fibrosarcoma case report has shown the importance of early diagnosis and targeted therapy (Photo courtesy of Sultana and Sailaja/Oncoscience)

Accurate Pathological Analysis Improves Treatment Outcomes for Adult Fibrosarcoma

Adult fibrosarcoma is a rare and highly aggressive malignancy that develops in connective tissue and often affects the limbs, trunk, or head and neck region. Diagnosis is complex because tumors can mimic... Read more

Technology

view channel
Image: Conceptual design of the CORAL capsule for microbial sampling in the small intestine (H. Mohammed et al., Device (2025). DOI: 10.1016/j.device.2025.100904)

Coral-Inspired Capsule Samples Hidden Bacteria from Small Intestine

The gut microbiome has been linked to conditions ranging from immune disorders to mental health, yet conventional stool tests often fail to capture bacterial populations in the small intestine.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.